Mannkind News
Most Popular Mannkind Story
Afrezza - FDA's top 10 Blockbuster Decisions
Drug: AfrezzaCompany: MannKindPDUFA date: December 29Peak sales: Difficult to project Usually the first word you hear when you mention Afrezza is "Exubera," Pfizer's failed attempt at introducing the
Read more...Latest Headlines
- September 23, 2011
- August 12, 2011
- February 10, 2011
- January 25, 2011
- January 20, 2011
- January 5, 2011
- December 29, 2010
- November 22, 2010
- November 5, 2010
- October 11, 2010
- August 20, 2010
- August 20, 2010
- July 20, 2010
- March 15, 2010
- February 2, 2010
- January 13, 2010
- January 11, 2010
- January 6, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
